卵巢癌分子靶向治疗研究进展

Research progress on targeted agents of ovarian cancer treatment

紫杉醇类和铂类化疗药物相结合是目前卵巢癌的主要治疗手段,但存在严重的不良反应及耐药性,很难提高患者的生存率。近年来,针对聚腺苷二磷酸核糖聚合酶(PARP)、血管内皮生长因子受体(VEGFR)、Wee1蛋白激酶、Src激酶和PI3K-AKT-m TOR信号通路的酪氨酸激酶抑制剂、单克隆抗体和多肽等已成为研发热点,分子靶向治疗有望增强肿瘤杀伤效果,延长患者的生存期。本文就卵巢癌的分子靶向治疗形势和未来的方向进行探讨。

Chemotherapy in ovarian cancer typically consists of platinum-based drugs, combined with paelitaxel or docetaxel. However, serious adverse reaction and drug resistance made rarely improvement of patient survival. Nowadays, novel agents （TKIs, monoclonal antibodies and peptides） targeting on PARP, VEGFR, Weel and PI3K- AKT- mTOR signaling pathways have become study hotspots. Molecular targeted therapy is suggested to enhance the inhibition effect and prolong the overall survival of ovarian cancer. This study reviewed targeted therapies in ovarian cancer in order to know about the current situation and the prospective research of the treatment in ovarian cancer.